Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac etalhyaluronate - Seikagaku Corporation

Drug Profile

Diclofenac etalhyaluronate - Seikagaku Corporation

Alternative Names: Diclofenac etalhyaluronate sodium - Seikagaku Corporation; Hyaluronic acid/non-steroidal anti-inflammatory drug; Hyaluronic acid/NSAID; JOYCLU; ONO 5704; ONO-5704/SI-613; SI-613; SI-613-ETP

Latest Information Update: 30 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seikagaku Corporation
  • Developer Ono Pharmaceutical; Seikagaku Corporation
  • Class Amides; Analgesics; Antirheumatics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis
  • Discontinued Tendinitis

Most Recent Events

  • 30 Nov 2022 Discontinued - Phase-II for Tendinitis in Japan (Intra-articular) (Seikagaku Corporation pipeline, November 2022)
  • 30 Sep 2022 Seikagaku Corporation plans clinical trial in Osteoarthritis in China and South Korea
  • 01 Feb 2022 Seikagaku Corporation terminates a Phase IIb for Tendinitis (Enthesopathy) in Japan, as the trial did not meet the primary efficacy endpoint (Seikagaku Corporation pipeline, November 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top